SWITCHDIN
SwitchDin, an Australian energy management software company, has been retained by distribution networks, SA Power Networks and AusNet Services, to provide a global-first solution that will allow networks to create flexible solar export limits to accommodate the growth of rooftop solar photovoltaic (PV) systems that are connected to the grid.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005065/en/
The installation of PV systems is growing at a rate of more than 200,000 each year in Australia’s National Electricity Market (NEM), and distribution networks are reaching the limit of their ability to host rooftop solar in some areas. This flexible export capability will allow SA Power Networks and AusNet Services to offer an alternative to the strict export limits currently required to address these challenges, increasing the penetration of renewable energy, creating more value for customers and improving the security of the grid.
The project is backed with over A$2 million in direct funding by the Australian Renewable Energy Agency (ARENA), with additional financial contributions from SwitchDin, SA Power Networks, AusNet Services and inverter manufacturers involved in the program. A 12 month trial involving a group of 600 customers in South Australia and Victoria will test the viability of this approach so it can be offered as a standard service to solar customers in future.
SwitchDin will lead in the project’s integration architecture design and will provide the core software platform for SA Power Networks and AusNet Services to support the flexible export functionality, based on the international ‘Smart Grid’ standard IEEE 2030.5. The flexible export capability will be enabled for solar inverters through connection to SwitchDin’s Droplet controller devices, or by connection via the internet into SwitchDin’s IEEE 2030.5 utility server platform.
Dr Andrew Mears, CEO of SwitchDin said, “SwitchDin is proud to be developing the technology backbone of the Flexible Exports project in South Australia and Victoria. This is another example of how we are working with Australia’s most progressive network service companies and the world’s best inverter manufacturers to bring smart software solutions to maximise the value of distributed energy resources such as rooftop solar for consumers and energy service providers alike.
“SwitchDin’s goal is to deliver smarter and cheaper clean energy services on the grid for the benefit of everyone. In the Australian market, the pressing issue is high penetration of rooftop solar, but our platform can also support battery storage and key loads such as heat pumps and electric vehicles as part of a complete ‘energy flexibility’ toolkit.”
“We want more solar, not less,” said Paul Roberts, Manager Corporate Affairs at SA Power Networks. “SA Power Networks is passionate about supporting South Australia’s energy transition and we have a number of initiatives underway that have the potential to double the amount of renewable energy the SA electricity distribution network can accommodate over the next five years.”
“By working with SwitchDin and the other project partners, SA Power Networks and AusNet Services are paving the way for distribution networks to continue to host the rooftop solar systems being installed by customers whilst reducing the need for major investment in network upgrades. This is a winning value proposition for energy distribution network companies globally who are grappling with how to meet customers’ expectations to be more energy independent.”
Building on past successes
SwitchDin solves one of the great roadblocks faced by today’s electricity system, the management at-scale of many distributed energy resources such as small-scale solar, batteries and loads like electric vehicles and HVAC systems. The company’s technology bridges the gap between traditional energy utilities, manufacturers and energy end-users by bringing rich data, intelligence and real-time fleet control capabilities to these assets.
In addition to the Flexible Exports project, SwitchDin is actively working with utilities and equipment manufacturers from around the world to build the grid of the future. The company connects and manages distributed assets with its Droplet controllers and smart software and provides cloud-level orchestration using its StormCloud management platform. SwitchDin can connect with upstream third party and utility distribution management systems or energy trading tools to ensure a smooth transition to clean and affordable electricity.
Note to Editor: Hi-res images can be downloaded here .
About SwitchDin:
SwitchDin is an energy technology company that plays a critical role in the energy transition by making distributed energy resources (DERs) such as solar PV and battery storage smart, visible and controllable. SwitchDin is paving the way for the integration of more renewables into the world’s energy system. Working in collaboration with energy utilities, equipment manufacturers, technology providers and facility managers, SwitchDin’s virtual power plant and microgrid management platform delivers new partnerships that unlock value for everyone connected to the grid. www.switchdin.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005065/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
